MeiraGTx Holdings plc recently shared a corporate presentation outlining its late-stage clinical pipeline and end-to-end capabilities in genetic medicine technologies. The presentation highlights a broad program pipeline across neuro, salivary gland, and ophthalmology, with four pivotal stage programs focusing on Parkinson's disease, radiation-induced xerostomia, AIPL1 retinal dystrophy, and X-linked retinitis pigmentosa. MeiraGTx's preclinical pipeline includes diverse programs targeting ALS, obesity, Stargardt's, and wet AMD. The company emphasizes its in-house manufacturing capabilities, featuring two cGMP viral vector manufacturing facilities, in-house cGMP plasmid production, and a commercially-licensed QC facility. The presentation also discusses next-generation vector optimization and proprietary riboswitch technology for titratable control of gene expression. Expected near-term global BLA filings are projected for AIPL1 congenital blindness and RPGR X-linked RP in 2025, radiation-induced xerostomia in 2026, and Parkinson's disease in 2027. You can access the full presentation through the link below.